Ignite Creation Date:
2025-12-24 @ 11:52 AM
Ignite Modification Date:
2026-01-01 @ 12:47 PM
Study NCT ID:
NCT04969861
Status:
TERMINATED
Last Update Posted:
2023-01-12
First Post:
2021-07-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Sponsor:
Nektar Therapeutics
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-09
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-04-22
Completion Date Type:
ACTUAL
First Submit Date:
2021-07-09
First Submit QC Date:
None
Study First Post Date:
2021-07-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-10-24
Results First Submit QC Date:
None
Results First Post Date:
2022-12-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-12-16
Last Update Post Date:
2023-01-12
Last Update Post Date Type:
ACTUAL